The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
At the time those predictions were being made Padlock Therapeutics (pre clinical and same sort of tech as modi but for autoimmune disease sold for $600 Million. As we were told by scancell clinical assets are worth 10x pre clinical. At the time, pre Redmile there were far less shares in issue so a 8 Bill mcap based on a clinically successful modi was not beyond the realms of possibility, and that didn't even include Scib or the MAB platform we now have.
Why are you so certain JB? The board departures are logical without them being a pre-curser to a sale of the company. Equally Scancell are recruiting for several positions which I'm not sure would be the case if a sale was imminent.
At this stage given the 8 year wait surely we'd wait for Modi1 and Scib1 trial data before selling up. If either, but particularly Modi1 goes as we hope, the potential sell out deal would be for a far far higher amount. I know there's always a risk the trials aren't as successful as we hope/expect but we are within touching distance of finding out if we have the holy grail...
I've been out of here for a little while as had to sell a lot of my stocks to buy a house. But glad to be back with a small buy on the open this morning.
As one of the posters mentioned this morning... just wait till they value Moditope!!!
Also Lindy seems to have been totally vindicated in holding out for a better deal, and with this deal in place we are much better placed to ward off a low ball offer to buy out the company which I had been fearing.